The Food and Drug Administration (FDA) is currently considering an Investigational New Drug (IND) Application from Mindstate Design Labs (Mindstate) for a Phase I human trial of its psychedelic drug 5-MeO-Mi also known as moxy. The IND Application and proposed trial is unique in that Mindstate selected this drug candidate through the use of artificial intelligence (AI) and machine learning (ML). Mindstate reports that it analyzed more than 70,000 “trip reports” from psychedelic users, sourced from diverse online platforms, to understand the subjective effects and states of consciousness induced by these substances.
Using large language models and natural language processing, Mindstate created a platform that can segment experiences based on the drug or psychedelic receptors involved. This segmentation allows for a greater understanding of how different substances affect consciousness. By leveraging AI and ML to experiment with these new states, the company aims to uncover potential therapeutic applications for psychedelic drugs which were previously unexplored.
The company proposes combining psychedelics with generic drugs to achieve precise consciousness. Its hypothesis is that this type of therapy could lead to more effective treatments for a variety of mental health conditions, including anxiety, depression and post-traumatic stress disorder, which are currently challenging to address with traditional psychedelics and other clinical treatment methods.
Mindstate’s use of AI and ML to evaluate data in support of its IND Application is groundbreaking, especially when it comes to drug development to target neurological and psychology conditions.
To read more about Mindstate Design Labs’ pioneering work, check out the full article on Fierce Biotech.
Please contact the authors if you have questions regarding the topic discussed, U.S. based and global clinical trials, or U.S. and E.U. data privacy and protection laws and AI governance issues.
